Xarelto, manufactured by Janssen Pharmaceuticals, is a drug prescribed to treat strokes and blood clots in patients diagnosed with atrial fibrillations (arrhythmia of the heart), deep vein thrombosis, and pulmonary embolism. However, Xarelto has been linked to many cases of gastrointestinal bleeding, and there is no antidote.
“Despite being armed with this data – armed with information that could save thousands of lives – the makers of Xarelto are withholding this information from patients, doctors and regulators,” commented lawyerNed McWilliams, a partner with the Levin, Papantonio law firm who practices in the areas of personal injury and pharmaceutical litigation.
Xarelto is an anti-blood clotting drug and has been linked to the same medical complications associated with similar drugs, including abdominal bleeding, rectal bleeding, brain hemorrhage, and abnormal lover function. Those associated risks coupled with Xarelto’s claims that close blood monitoring or doctor follow ups proves to be very dangerous for patients.
Also, Xarelto has no anticote to reverse internal bleeding. For decades, the gold standard of anti-clotting drugs was Warfarin, for which there was an antidote of simple vitamin K therapy to treat internal bleeding and encourage clotting.
Meanwhile, the company that manufactures Xarelto hasn’t done anything to provide information to doctors on how to properly treat internal bleeding. And the company continues to gross billions of dollars.